Skip to main content

Table 2 Monoclonal antibodies for relapsing-remitting multiple sclerosis (RRMS)

From: Recent developments in multiple sclerosis therapeutics

Agent

Proposed mechanisms of action

Stage of development*

Alemtuzamab

Leukocyte depletion; Depletes CD52 B and T cell populations, monocytes, macrophages and eosinophils

Phase III for RRMS

Daclizumab

Leukocyte depletion; Binds cell-surface receptor IL2; reduces T cell proliferation and activation

Phase II for RRMS

Rituximab

B cell-directed therapy; Depletes CD20 B cell population

Phase III for RRMS

  1. *Compiled from http://www.clinicaltrials.gov